Skip to main content
Calliditas Therapeutics logo

Calliditas Therapeutics — Investor Relations & Filings

Ticker · CALTX ISIN · SE0010441584 LEI · 549300PVPZO8TNT76B58 ST Manufacturing
Open in API
Filings indexed 282 across all filing types
Latest filing 2019-08-15 Interim / Quarterly Rep…
Country SE Sweden
Listing ST CALTX

About Calliditas Therapeutics

https://www.calliditas.se/en/

Calliditas Therapeutics is a commercial-stage biopharmaceutical company focused on identifying, developing, and commercializing novel treatments for rare diseases with significant unmet medical needs. The company concentrates on orphan indications, with an initial focus on renal and hepatic diseases. Its lead product, TARPEYO® (budesonide), is approved in the U.S. for the treatment of primary immunoglobulin A nephropathy (IgAN) and is marketed as Kinpeygo® in Europe. Calliditas is advancing a pipeline of novel medications and seeks strategic partnerships to expand its development and commercialization efforts for therapies addressing conditions with few or no existing approved treatments.

Recent filings

Filing Released Lang Actions
Interim / Quarterly Report 2019
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Interim Report January 1 – June 30, 2019' for Calliditas Therapeutics AB. It contains comprehensive financial data, including net sales, net income, earnings per share, and cash equivalents for the specified period. It also includes a CEO statement, business overview, and details on clinical trials. This fits the definition of an Interim/Quarterly Report (IR) as it provides substantive financial statements and analysis for a period shorter than a full fiscal year. H1 2019
2019-08-15 English
Strategisk inlicensiering relaterad till autoimmun hepatit för den amerikanska marknaden
Regulatory Filings Classification · 100% confidence The document is a press release dated August 12, 2019, announcing a strategic in-licensing agreement between Calliditas Therapeutics AB and Dr. Falk Pharma GmbH regarding a drug for the US market, specifically mentioning autoimmune hepatitis (AIH). It details financial terms (initial payment, total deal value, royalties) and future regulatory steps (meeting with the FDA). The text concludes with a statement indicating it is information the company is obligated to disclose under the EU Market Abuse Regulation ('EU:s marknadsmissbruksförordning'). This structure—a formal announcement of a significant business event (licensing/financing) that is not a full financial report (like 10-K or IR) or a general regulatory filing (RNS)—best fits the 'Capital/Financing Update' category, as licensing deals often involve significant upfront payments and future milestones, impacting capital structure or financing strategy. It is not a standard Earnings Release (ER), Interim Report (IR), or a general Regulatory Filing (RNS), but rather a specific corporate action announcement related to asset acquisition/financing.
2019-08-12 Swedish
Strategic in-licensing related to autoimmune hepatitis in the US market
Regulatory Filings Classification · 95% confidence The document is a press release dated August 12, 2019, announcing a strategic in-licensing deal between Calliditas Therapeutics and Dr. Falk Pharma GmbH regarding Budenofalk for the US market. It details financial terms (€1.5m upfront, €40m total value), regulatory plans (meeting with the FDA planned for Q1 2020), and the indication (autoimmune hepatitis - AIH). This type of announcement, detailing a significant business transaction (licensing/partnership) and associated financial/regulatory milestones, falls under Capital/Financing Update (CAP) or potentially Regulatory Filings (RNS) if no other category fits well. Since it involves a significant financial agreement and future capital deployment/milestones, CAP is a strong candidate. However, the core event is a business development/licensing deal, which is often categorized under general corporate actions. Given the options, 'CAP' (Capital/Financing Update) covers fundraising and financing activities, which licensing deals often relate to, but 'RNS' (Regulatory Filings) is a broad category for corporate announcements. Looking closely at the definitions, none perfectly capture 'M&A Activity' (TAR) or 'Financing' (CAP) as clearly as a licensing deal. Since it is a major corporate announcement regarding a strategic asset acquisition/licensing, and it is not a standard financial report (10-K, IR, ER), it is best classified as a general Regulatory Filing (RNS) or potentially TAR if the licensing is viewed as a major transaction, but TAR is defined for M&A/takeover bids. Given the nature of the announcement (a press release detailing a strategic deal), RNS is the most appropriate fallback for significant, non-standard corporate news that doesn't fit the specific financial report codes. However, since the deal involves significant financial commitments (€40m potential value), CAP is also plausible. I will lean towards RNS as the most general fit for a strategic corporate press release that isn't a standard financial report or management change.
2019-08-12 English
Antal aktier och röster i Calliditas Therapeutics
Share Issue/Capital Change Classification · 99% confidence The document is a short announcement in Swedish regarding the total number of shares and votes in Calliditas Therapeutics AB as of July 31, 2019, following a directed share issue. This type of announcement, detailing changes in the total share count due to capital structure adjustments (like a directed share issue), directly relates to the company's capital structure or share count. This aligns best with the 'Share Issue/Capital Change' category (SHA). It is not a full report (10-K, IR), an earnings release (ER), or a dividend notice (DIV). Given the specific nature of reporting the total share count after an issuance, SHA is the most precise fit.
2019-07-31 Swedish
Number of shares and votes in Calliditas Therapeutics
Declaration of Voting Results & Voting Rights Announcements Classification · 99% confidence The document is a short press release dated July 31, 2019, announcing a change in the total number of shares and votes due to a directed share issue completed in early July 2019. This directly relates to a change in the company's capital structure (share count). This fits the definition of 'Share Issue/Capital Change' (SHA). It is not a full financial report (10-K, IR), an earnings release (ER), or a general regulatory filing (RNS), as it pertains to a specific capital event.
2019-07-31 English
Major Shareholding Notification 2019
Major Shareholding Notification Classification · 99% confidence The document details a change in shareholding percentage by an individual, Mark Lampert, in Calliditas Therapeutics AB. It explicitly mentions 'Reason for major shareholding notification Buy' and provides detailed tables showing the 'Before the transaction' and 'After the transaction' holdings, including the total number of shares and the resulting percentage (e.g., 4.82075%). This structure is characteristic of a notification regarding a change in significant ownership, which aligns with the definition for Major Shareholding Notification (MRQ). The document is not a full annual report (10-K), an earnings release (ER), or a proxy statement (DEF 14A/PSI).
2019-07-05 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.